Fibroblast growth factor receptors, developmental corruption and malignant disease
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Fibroblast growth factor receptors, developmental corruption and malignant disease
Authors
Keywords
-
Journal
CARCINOGENESIS
Volume 34, Issue 10, Pages 2198-2205
Publisher
Oxford University Press (OUP)
Online
2013-07-25
DOI
10.1093/carcin/bgt254
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tumor-Specific Isoform Switch of the Fibroblast Growth Factor Receptor 2 Underlies the Mesenchymal and Malignant Phenotypes of Clear Cell Renal Cell Carcinomas
- (2013) Q. Zhao et al. CLINICAL CANCER RESEARCH
- Fibroblast Growth Factor Receptor Inhibitors as a Cancer Treatment: From a Biologic Rationale to Medical Perspectives
- (2013) Maria Vittoria Dieci et al. Cancer Discovery
- A Phase I Dose-Escalation Study of Regorafenib (BAY 73-4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors
- (2012) K. Mross et al. CLINICAL CANCER RESEARCH
- Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma
- (2012) R. S. Finn et al. CLINICAL CANCER RESEARCH
- Fibroblast Growth Factor Receptor Inhibitors
- (2012) Suneel Kumar B.V.S et al. CURRENT PHARMACEUTICAL DESIGN
- A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets
- (2012) Niantao Deng et al. GUT
- Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status
- (2012) She-Juan An et al. PLoS One
- Selfish Spermatogonial Selection: Evidence from an Immunohistochemical Screen in Testes of Elderly Men
- (2012) Jasmine Lim et al. PLoS One
- Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma
- (2012) D. Singh et al. SCIENCE
- FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor
- (2012) V. Guagnano et al. Cancer Discovery
- Phase II, Open-Label Study of Brivanib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma
- (2011) J.-W. Park et al. CLINICAL CANCER RESEARCH
- A Novel, Selective Inhibitor of Fibroblast Growth Factor Receptors That Shows a Potent Broad Spectrum of Antitumor Activity in Several Tumor Xenograft Models
- (2011) G. Zhao et al. MOLECULAR CANCER THERAPEUTICS
- Targeting mutant fibroblast growth factor receptors in cancer
- (2011) Heidi Greulich et al. TRENDS IN MOLECULAR MEDICINE
- Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
- (2011) Peter S. Hammerman et al. Cancer Discovery
- Phase I Open-Label Study of Continuous Treatment with BIBF 1120, a Triple Angiokinase Inhibitor, and Pemetrexed in Pretreated Non-Small Cell Lung Cancer Patients
- (2010) P. M. Ellis et al. CLINICAL CANCER RESEARCH
- A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer
- (2010) Lambertus A Kiemeney et al. NATURE GENETICS
- Rapidly Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in NSCLC Cell Lines through De-Repression of FGFR2 and FGFR3 Expression
- (2010) Kathryn E. Ware et al. PLoS One
- Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
- (2010) J. Weiss et al. Science Translational Medicine
- Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate
- (2009) Punit H. Marathe et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Crystal Structure of a Fibroblast Growth Factor Homologous Factor (FHF) Defines a Conserved Surface on FHFs for Binding and Modulation of Voltage-gated Sodium Channels
- (2009) Regina Goetz et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- FGFR2 Abnormalities Underlie a Spectrum of Bone, Skin, and Cancer Pathologies
- (2009) Masaru Katoh JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors
- (2009) Anne Goriely et al. NATURE GENETICS
- The FGF family: biology, pathophysiology and therapy
- (2009) Andrew Beenken et al. NATURE REVIEWS DRUG DISCOVERY
- Common Breast Cancer-Predisposition Alleles Are Associated with Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
- (2008) Antonis C. Antoniou et al. AMERICAN JOURNAL OF HUMAN GENETICS
- Inhibition of Fibroblast Growth Factor 19 Reduces Tumor Growth by Modulating -Catenin Signaling
- (2008) R. Pai et al. CANCER RESEARCH
- BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
- (2008) F. Hilberg et al. CANCER RESEARCH
- Brivanib Alaninate, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Tyrosine Kinases, Induces Growth Inhibition in Mouse Models of Human Hepatocellular Carcinoma
- (2008) H. Huynh et al. CLINICAL CANCER RESEARCH
- WNT Signaling in Stem Cell Biology and Regenerative Medicine
- (2008) Masaru Katoh CURRENT DRUG TARGETS
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Drug-sensitive FGFR2 mutations in endometrial carcinoma
- (2008) A. Dutt et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started